Imifoplatin
Based on 1 Customer Validation
Imifoplatin (PT-112) is a platinum-based active molecule and a member of the phosphaplatins family. Imifoplatin can induce Apoptosis and exhibits antitumor activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 95.0%
- No. CAS: 1339960-28-9
- Fòrmula: C6H16N2O7P2Pt
- Peso molecular:485.23
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Actividad biológica
Descripciòn
In Vitro
Imifoplatin (5–20 µM, 72 hours) shows dose-dependent proliferation inhibition in HCT116 cells[2]. Imifoplatin (10 µM, 24 hours) significantly induces apoptosis in HCT116 cells[2]. Imifoplatin (0.287–222.14 µM, 72 hours) significantly inhibits proliferation in CT26 cells[2]. Imifoplatin (2–10 μM, 24–72 hours) has notable selectivity, showing strong inhibition of glycolytic tumor cells with mtDNA mutations[3]. Imifoplatin (10 μM, 48–72 hours) significantly increases mtROS, especially in glycolytic L929dt and Cybrid cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Mouse fibroblast L929, mtDNA mutant L929dt, and Cybrid cells
-
Concentration:2, 6, 10 μM
-
Incubation Time:24–72 hours
-
Result:Inhibited L929dt and Cybrid cells by about 80% after 48 hours, while inhibition in OXPHOS-competent L929 cells was lower.
-
Cell Line:HCT116 (human colorectal cancer cells)
-
Concentration:5, 10, 20 µM
-
Incubation Time:72 hours
-
Result:Significantly inhibited cell proliferation at higher concentrations.
-
Cell Line:HCT116 (human colorectal cancer cells)
-
Concentration:10 µM
-
Incubation Time:24 hours
-
Result:Increased proportions of early and late apoptotic cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MC38 colorectal carcinoma xenograft model in C57BL/6J mice[2]
-
Dosage:90 mg/kg
-
Administration:Intravenous injection (i.v.), once weekly for 7 weeks
-
Result:Inhibited tumor growth, extended survival; further enhanced survival when combined with PD-1 blockade (Avelumab (HY-108730)).
-
Animal Model:CT26 colorectal carcinoma xenograft model in BALB/c mice[2]
-
Dosage:90 mg/kg
-
Administration:Intravenous injection (i.v.), once weekly for 5 weeks
-
Result:Significantly inhibited tumor growth, increased T-cell infiltration, reduced immunosuppressive TAMs.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1339960-28-9
-
Appearance Solid
-
Peso molecular 485.23
-
Fòrmula C6H16N2O7P2Pt
-
Color White to off-white
-
SMILES
O=[P]([O-][Pt+2]1([O-][P]2(O)=O)[NH2][C@@](CCCC3)([H])[C@]3([H])[NH2]1)(O2)O
-
Synonyms
PT-112
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
In Vitro:
H2O : 1.25 mg/mL (2.58 mM; Need ultrasonic; DMSO can inactivate Imifoplatin's activity)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocolo
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Pureza y Documentación
-
Ficha de datos (284 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[2]. Yamazaki T, et al. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020 Feb 11;9(1):1721810. [Content Brief]
[3]. Soler-Agesta R, et al. PT-112 induces mitochondrial stress and immunogenic cell death, targeting tumor cells with mitochondrial deficiencies[J]. Cancers, 2022, 14(16): 3851. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.0609 mL | 10.3044 mL | 20.6088 mL | 51.5220 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.